A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical trial NCT05381935 · WITHDRAWN

Trial details

NCT number: NCT05381935
Sponsor: Elpiscience Biopharma, Ltd.
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2023-04-21
Primary completion: 2026-04-30
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.